- Home
- BTAI vs TPST Comparison
BTAI vs TPST Comparison
Compare BTAI & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- TPST
- Stock Information
- Founded
- BTAI 2017
- TPST 2011
- Country
- BTAI United States
- TPST United States
- Employees
- BTAI N/A
- TPST N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- TPST Health Care
- Exchange
- BTAI Nasdaq
- TPST Nasdaq
- Market Cap
- BTAI 48.3M
- TPST 45.5M
- IPO Year
- BTAI 2018
- TPST N/A
- Fundamental
- Price
- BTAI $2.07
- TPST $10.82
- Analyst Decision
- BTAI Buy
- TPST Hold
- Analyst Count
- BTAI 5
- TPST 3
- Target Price
- BTAI $32.80
- TPST $30.00
- AVG Volume (30 Days)
- BTAI 1.0M
- TPST 44.9K
- Earning Date
- BTAI 11-13-2025
- TPST 11-07-2025
- Dividend Yield
- BTAI N/A
- TPST N/A
- EPS Growth
- BTAI N/A
- TPST N/A
- EPS
- BTAI N/A
- TPST N/A
- Revenue
- BTAI $868,000.00
- TPST N/A
- Revenue This Year
- BTAI N/A
- TPST N/A
- Revenue Next Year
- BTAI $614.78
- TPST N/A
- P/E Ratio
- BTAI N/A
- TPST N/A
- Revenue Growth
- BTAI N/A
- TPST N/A
- 52 Week Low
- BTAI $1.17
- TPST $5.35
- 52 Week High
- BTAI $13.28
- TPST $15.73
- Technical
- Relative Strength Index (RSI)
- BTAI 34.40
- TPST 53.27
- Support Level
- BTAI $2.14
- TPST $10.58
- Resistance Level
- BTAI $2.46
- TPST $11.13
- Average True Range (ATR)
- BTAI 0.17
- TPST 0.67
- MACD
- BTAI 0.00
- TPST -0.04
- Stochastic Oscillator
- BTAI 2.64
- TPST 34.32
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.